For several months, SARS-CoV-2 virus infection, which sometimes causes critical COVID-19 disease primarily with lung involvement, has been the one and only medical and scientific topic. The widespread occurrence of this type of coronavirus has led to a global pandemic and a huge social confusion that has had and will have a significant impact on our lives.

From the point of view of a specialist in rheumatology and internal medicine, currently performing duties of a medical doctor of infectious diseases in the department of rheumatology in a temporarily uniform hospital in Poznań, Poland, various questions and reflections arise.

Does coronavirus, which turned out to be the greatest celebrity of the modern world, have any connection with the field of rheumatology? Do patients with rheumatic diseases have a higher risk of being infected with SARS-CoV-2 virus and developing COVID-19 disease? Does the standard treatment of synthetic and biological drugs that modifies autoimmune multiorgan inflammation have such a negative impact on the immune system that it could be a threat to rheumatological patients?

The developing infection from the rheumatologist's point of view seems to be understandable both at the stage of the mechanism of coronavirus entry through the ACE-2 receptor, which is distributed in epithelial cells of various systems and organs, as well as the mechanism of intracellular endocytosis with uncontrolled viral replication. Similarly, a subsequent immune dysregulation mechanism is characterized by a decrease in the concentration of type I and III antiviral interferons and excessive activation of primarily Th2 lymphocytes and signal transmission to B lymphocytes, which leads to a cytokine storm with symptoms of rapidly progressing pneumonia. At each of these stages of the disease, drugs that have been widely used by rheumatologists for many years could be implemented, and up until the global era of SARS-CoV-2 these drugs were uncommon in clinical practice of infectious disease physicians.

Chloroquine or hydroxychloroquine may have an in vitro antiviral effect by increasing lysosomal pH as well as by causing ACE-2 receptor glycosylation disorders, which leads to inhibition of SARS-CoV-2 fusion and replication. Another postulated mechanism is the inhibition of coronavirus accumulation in the structure of the endoplasmic reticulum called the ER-Golgi intermediate compartment (ERGIC), as well as inhibition of the expression of phosphatidylinositol binding the clathrin protein into the PICALM complex taking an active part in the process of SARS-CoV-2 endocytosis \[[@cit0001]--[@cit0003]\]. Certainly, the mechanism of blocking signaling of toll-like receptors and pro-inflammatory cytokine outbreak well known from rheumatology is also applicable here.

Unfortunately, despite previous reports, currently conducted in vivo clinical observational studies have not yet confirmed the effectiveness and safety of this therapy in both the treatment and prevention of SARS-CoV-2 infection. Additionally, analyses of large international registries suggest a lack of clinical efficacy of anti-malarial drugs in the treatment of COVID-19, and even an increased risk of death or life-threatening ventricular arrhythmias \[[@cit0004]\]. However, this published data is very controversial and requires extensive scientific discussion. The results of randomized trials that will give us more insights on clinical efficacy should be expected in the near future.

The weakening of the acute phase response in COVID-19 disease may also be associated with the inhibition caused by Janus kinase inhibitors (baricitinib, ruxolitinib, fedratinib) of clathrin-dependent viral endocytosis to pneumocytes regulated by the Numb-associated kinase (NAK family) \[[@cit0005]\].

In the treatment of cytokine storm in COVID-19, there is a possibility of using a TNF alpha inhibitor (adalimumab) or IL-6 receptor inhibitors (tocilizumab, sarilumab) \[[@cit0006]--[@cit0008]\], which are currently being studied in randomized clinical trials in SARS-CoV-2 infected patients with signs and symptoms of rapidly progressing pneumonia. IL-1 (anakinra) inhibitor \[[@cit0009]\], mycophenolate mofetil, tofacitinib, or IVIG infusions, as well as colchicine have also been used in described individual cases or larger groups of patients (non-commercial clinical studies) \[[@cit0010]\].

Our own experience with the combined use of chloroquine and azithromycin or ceftriaxone (*n* = 34) and tocilizumab (*n* = 1) in the treatment of severe pneumonia in the course of COVID-19 disease is very good, although it should only be considered as a series of cases ([Figs. 1](#f0001){ref-type="fig"} and [2](#f0002){ref-type="fig"}, [Table I](#t0001){ref-type="table"}). In our opinion, the treatment was effective and safe. Moreover, the analysis of the causes of death of our COIVID-19 patients (*n* = 3), especially in the context of the concurrent use of chloroquine and azithromycin, showed that only in one case at the time of death the patient received 250 mg of chloroquine twice a day for 8 days, and no arrhythmias were found in this particular case.

![A 30-year-old woman with severe COVID-19 pneumonia before treatment. HRCT performed on 21^st^ April, 2020.](RU-58-96685-g001){#f0001}

![A 30-year-old woman with severe COVID-19 pneumonia after treatment with chloroquine, azithromycin, lopinavir + ritonavir, tocilizumab, methylprednisolone for consecutive days. HRCT performed on 30^th^ April, 2020.](RU-58-96685-g002){#f0002}

###### 

Treatment scheme of 30-year-old female patient with severe COVID-19 pneumonia

  Drug name and dose   Time                                                               Start         Finish       13.04.2020   20.04.2020   27.04.2020                                                            
  -------------------- ------------------------------------------------------------------ ------------- ------------ ------------ ------------ ------------ -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --
                       Patient hospitalization                                            17 days       17.04.2020   4.05.2020                                                                                       
                       Positive RT-PCR SARS-CoV-2 tests                                   1 instance    17.04.2020   17.04.2020                                                                                      
  1                    Chloroquine 2 × 500 mg/day                                         5 days        17.04.2020   21.04.2020                                                                                      
  1                    Chloroquine 2 × 250 mg/day                                         5 days        22.04.2020   26.04.2020                                                                                      
  2                    Azithromycin 1 × 500 mg/day                                        3 days        17.04.2020   19.04.2020                                                                                      
  2                    Azithromycin 1 × 250 mg/day                                        4 days        20.04.2020   24.04.2020                                                                                      
  3                    Lopinavir + ritonavir 2 × 500 mg/day                               7 days        21.04.2020   28.04.2020                                                                                      
  4                    Tocilizumab 480 mg/day[\*](#tf1-1){ref-type="table-fn"}            2 days        22.04.2020   23.04.2020                                                                                      
  5                    Methylprednisolone 125 mg/day[\*\*](#tf1-2){ref-type="table-fn"}   3 days        24.04.2020   26.04.2020                                                                                      
                       Negative RT-PCR SARS-CoV-2 tests                                   2 instances   1.05.2020    2.05.2020                                                                                       

two separated doses 8 mg/kg every 12--24 h

for 3 consecutive days.

In accordance with some clinical concerns of rheumatologists, patients with rheumatic diseases treated with disease-modifying drugs (DMARDs) should have a higher risk of SARS-CoV-2 infection. However, the first published studies from groups of patients from the region of Lombardy (Italy) and New York (USA) do not fully confirm these hypotheses. In the first case in the analyzed group of patients with rheumatic diseases (*n* = 320), only four cases of COVID-19 disease were confirmed. In the second case in the group of patients with ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis (*n* = 50) only one person died due to SARS-CoV-2 active infection \[[@cit0011], [@cit0012]\]. In our sample of patients (*n* = 49) hospitalized in the rheumatology ward between March 9^th^ 2020 and May 30^th^ 2020 with suspected or diagnosed coronavirus infection, no case of a patient with rheumatic disease was found. Similarly, only 2 such cases from Poland were registered in the EULAR COVID-19 database as of May 26^th^ 2020 \[[@cit0013]\].

Perhaps dysregulation of the immune system due to generalized inflammation and the use of immunosuppressive and biological drugs that reduce the activity of the disease are in some sense potential factors protecting against the development of active infection. At present, it appears that patients with rheumatic diseases do not have a higher risk of developing SARS-CoV-2 infection, particularly severe, compared to the general population risk.

On April 27^th^ 2020 by consensus of 5 specialists in the field of rheumatology from the Poznań Branch of the Polish Society of Rheumatology the following guidelines for treating rheumatic patients in the time of COVID-19 were proposed:

1.  **Patient** with pharmacologically treated rheumatic disease after close contact (staying at a distance of less than 2 m, for more than 15 minutes, in the last 7 days) with a person with confirmed SARS-CoV-2 infection **without clinical symptoms of COVID-19**:

    -   maintain treatment with chloroquine/hydroxychloroquine, salazopyrin/sulfasalazine, corticosteroids, NSAIDs (if necessary),

    -   in anticipation of negative SARS-CoV-2 test results (RT-PCR only) or after two weeks without clinical signs of COVID-19, **temporary discontinuation** of methotrexate, leflunomide and biological disease-modifying drugs (very high doubt about standard drug withdrawal recommendations in this situation) and Janus kinase inhibitors (very high doubt about standard withdrawal recommendations in this situation due to the use of these drugs in clinical trials in patients with COVID-19) **may be considered,**

    -   use of tocilizumab should be continued; the drug is used to treat COVID-19 in selected clinical situations (off-label) and is currently being tested in numerous clinical trials.

2.  **Patient** with pharmacologically treated rheumatic disease and **documented SARS-CoV-2 infection with or without COVID-19 symptoms**:

    -   maintain treatment with chloroquine/hydroxychloroquine, salazopyrin/sulfasalazine, corticosteroids, NSAIDs (if necessary),

    -   consult with the rheumatology department that treats patients with COVID-19,

    -   for patients with no clinical signs and symptoms of COVID-19, **temporary discontinuation** of methotrexate, leflunomide and biological disease-modifying drugs and Janus kinase inhibitors (tofacitinib, baricitinib) **may be considered;** at the same time, one should take into account the lack of an unambiguous standard of such proceedings,

    -   refer patients **with clinical symptoms of COVID-19** to the rheumatology ward that treats patients with COVID-19 and **discontinue** methotrexate, leflunomide and biological disease-modifying drugs as well as inhibitors of Janus kinases (tofacitinib, baricitinib); in the last case, one should have considerable doubt as to the standard of such proceedings with similar justification as above,

    -   in the absence of acute and very severe respiratory symptoms, it seems that the use of tocilizumab should be continued until hospitalization and further decisions.

Of course, the recommendations above are not based on strong scientific evidence, but solely on the analysis of currently available literature, reflection and own experience and should certainly be verified in the near future.

This time we are currently experiencing is very difficult, not only from a medical but also an organizational point of view. The celebrity virus has also reached the rheumatologists' environment, both in a purely scientific and also the most clinical context. However, we live with the hope that in Poland the time of COVID-19 is coming to an end and we will be able to return to our normal and everyday work in accordance with our medical specialization.
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